报价延迟最少15分钟:2025/07/12 21:26 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.23 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-5.88/-2.76
|
|
企业价值
527.54M
|
| 资产负债 |
|
每股账面净值
26.94
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/12 21:26 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency. |
